On this page
BBS9
Bardet-Biedl syndrome 9
BBS9 is located on the short (p) arm of chromosome 7, at band 7p14.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 7 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The BBS9 gene encodes a 887-amino acid protein that functions as a core component of the BBSome, a complex essential for the assembly and maintenance of primary cilia. Primary cilia are antenna-like projections found on the surface of most human cells, serving critical roles in signalling and sensory perception. When BBS9 function is disrupted through pathogenic variants, cells cannot properly assemble or maintain these structures, leading to a range of developmental and functional abnormalities.
Bardet-Biedl syndrome, the primary condition associated with BBS9 variants, follows an autosomal recessive inheritance pattern. This means individuals must inherit two altered copies of the gene - one from each parent - to develop the condition. Carriers, who possess one pathogenic variant alongside one functional copy, typically remain unaffected but can pass the variant to their children.
What the gene does
The BBS9 protein serves as a structural component of the BBSome, an octameric complex that coordinates the transport of membrane proteins to and from cilia. This transport function is critical for maintaining the unique protein composition of ciliary membranes, which differs substantially from the surrounding cell membrane. The BBSome acts as an adaptor, linking cargo proteins to the intraflagellar transport machinery that moves materials along the ciliary axoneme.
Within the BBSome complex, BBS9 contributes to the structural integrity and cargo-recognition capabilities of the assembly. The protein facilitates the selective retrieval of signalling receptors from ciliary membranes, a process essential for terminating certain signalling cascades and preventing aberrant pathway activation. Through these activities, BBS9 helps regulate multiple ciliary signalling pathways, including those involving G-protein coupled receptors and developmental morphogens. Disruption of these transport processes underlies the multisystem phenotype observed when BBS9 function is compromised.
Video: Genetics 101
Chromosome location
BBS9 is located on the short arm of chromosome 7 at position 14.3 (7p14.3). This chromosomal region contains several genes involved in developmental processes. The gene spans genomic sequence that encodes the 887-amino acid protein through multiple exons, with the coding sequence organised to produce a transcript expressed across many tissue types during development and throughout adult life.
Protein structure
The BBS9 protein contains a seven-bladed beta-propeller domain spanning amino acids 1 to 407, forming the N-terminal region of the protein. This structural motif creates a circular arrangement of beta-sheets that typically mediates protein-protein interactions. The central portion of BBS9 includes a region from amino acids 685 to 765 that facilitates interaction with LZTL1, a protein involved in regulating hedgehog signalling. The C-terminal end contains a disordered region from amino acids 850 to 887, which may provide flexibility for dynamic interactions with other BBSome components or regulatory proteins.
Key variants
Pathogenic variants in BBS9 are distributed across the gene, with most resulting in loss of protein function through premature termination, frameshift, or missense changes that disrupt the beta-propeller structure. Because Bardet-Biedl syndrome follows autosomal recessive inheritance, affected individuals carry pathogenic variants on both gene copies. The specific combination of variants can influence phenotypic severity, though considerable variability exists even among individuals with identical genotypes.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1022T>A | p.Leu341Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Bardet-Biedl syndrome 9 |
c.1099C>T | p.Gln367Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Bardet-Biedl syndrome |
c.1283_1286del | p.Thr428fs | Pathogenic/Likely pathogenic | ★★☆☆ | Bardet-Biedl syndrome |
c.1789+1G>C | - | Pathogenic/Likely pathogenic | ★★☆☆ | Bardet-Biedl syndrome |
c.196G>T | p.Glu66Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Bardet-Biedl syndrome |
c.2014C>T | p.Gln672Ter | Pathogenic | ★★☆☆ | Bardet-Biedl syndrome 9 |
c.2503_2504dup | p.Gln835fs | Pathogenic/Likely pathogenic | ★★☆☆ | Bardet-Biedl syndrome |
c.358C>T | p.Gln120Ter | Pathogenic | ★★☆☆ | Bardet-Biedl syndrome 9 |
c.434del | p.Gly145fs | Pathogenic/Likely pathogenic | ★★☆☆ | Bardet-Biedl syndrome |
c.966G>A | p.Trp322Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Bardet-Biedl syndrome |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Pathogenic variants in BBS9 cause Bardet-Biedl syndrome, a rare ciliopathy characterised by a constellation of clinical features that typically include retinal dystrophy leading to progressive vision loss, obesity often beginning in early childhood, polydactyly, renal abnormalities, learning difficulties, and genital abnormalities in males. The condition shows considerable phenotypic variability, with not all affected individuals manifesting every characteristic feature. Other manifestations may include diabetes mellitus, hypertension, and structural heart defects. The multisystem nature of the condition reflects the widespread importance of ciliary function across different organs and developmental stages.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic BBS9 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
BBS9 holds green classification status across multiple NHS Genomic Medicine Service panels, reflecting its established clinical validity for diagnostic testing. The gene appears on the Bardet-Biedl syndrome panel (R107), the Fetal anomalies panel (R21), the Intellectual disability panel (R29), and the Retinal disorders panel (R32), among others including panels for ophthalmological ciliopathies, renal ciliopathies, and severe early-onset obesity (R149). This broad panel membership reflects the diverse clinical presentations of BBS9-related conditions and ensures the gene is included when testing individuals with features consistent with ciliopathies.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
How is BBS9-related Bardet-Biedl syndrome inherited?
Bardet-Biedl syndrome caused by BBS9 variants follows autosomal recessive inheritance. An affected individual has inherited one pathogenic variant from each parent. Parents who each carry one variant typically show no symptoms but have a 25% chance with each pregnancy of having an affected child.
What is the BBSome and why does it matter?
The BBSome is a protein complex that transports molecules into and out of cilia, the microscopic projections on cell surfaces that function in signalling and sensation. BBS9 is one of eight core proteins forming this complex. When the BBSome cannot function properly, cells lose normal ciliary signalling, leading to the multisystem features of Bardet-Biedl syndrome.
Why does BBS9 appear on multiple NHS testing panels?
BBS9 appears on numerous NHS panels because pathogenic variants cause features affecting multiple organ systems - eyes, kidneys, brain development, limbs, and metabolism. This ensures clinicians testing for any of these features include BBS9 in their diagnostic evaluation, reflecting the variable presentation of ciliopathies.